About the Program
The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, expert review of the 68th American Association for the Study of the Liver Diseases Annual Meeting (AASLD 2017). This program will feature HCV experts reviewing and discussing the most important studies on chronic hepatitis C presented at AASLD 2017. This review and discussion will provide a comprehensive overview of each of the posters and presentations as selected by our faculty panel. In addition, the faculty will provide unique insights into how knowledgeable experts review and analyze data from AASLD and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.
This activity will enable participating health care providers caring for HCV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.
After completing this activity, the participant should be better able to:
Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at AASLD 2017
Employ the current treatment paradigms for CHC, including the studies and data presented at AASLD 2017, to improve patient care
Discuss with patients and colleagues the studies and data on newer therapies for CHC presented at AASLD 2017 to decide on appropriate planning of therapy for patients with CHC
Release Date: November 1, 2017
Expiration Date: November 1, 2018
Estimated time to complete this program: 15-30 minutes per module
Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Nezam H. Afdhal, MD
Professor of Medicine
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center
Beth Israel Deaconess Medical Center
Fred Poordad, MD
VP, Academic and Clinical Affairs
The Texas Liver Institute
Clinical Professor of Medicine
University of Texas Health Science Center
San Antonio, Texas
Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine I
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. There will be 8 posters and presentations available for a total of 2.00 possible credit hours.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors,
planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or apparent
conflict of interest (COI) they may have as related to the content of
this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Nezam Afdhal, MD
- Consulting Fees: Merck, Gilead, Echosens, Ligand, Janssen, Shionogi
- Employee/Salary: Sprint Bank Pharmaceuticals (Research Company)
- Other: Director-TRIO Healthcare
- Stock: Allurion, Spring Bank Pharmaceuticals
- Stock Options: SpringBank Pharmaceuticals, TRIO
Fred Poordad, MD
- Consulting Fees: Abbvie, Gilead, Merck, BMS, Salix
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents: Abbvie, Gilead, Merck, BMS, Salix
- Research Support: Abbvie, Gilead, Merck, BMS, Salix
Juergen Rockstroh, MD
- Consulting Fees: Abbott, Gilead, Hexal, Merck, ViiV
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents: Abbott, Gilead, Janssen, Merck
- Contracted Research: Gilead
Mark Sulkowski, MD
- Contracted Research (to JHU): Abbvie, Gilead, Merck, Tobira
- Consulting Fees: Abbvie, CoCrystal, Gilead, Janssen, Merck, Trek
- Other: Gilead - DSMB Member
The planners and managers
reported the following financial relationships or relationships to
products or devices they or their spouse/life partner have with
commercial interests related to the content of this CME activity:
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN and Jan
Schultz, MSN, RN, CHCP, have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and receved CME credit for this activity. During the period, November 1, 2017 through November 1, 2018 participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If
you wish to received acknowledgment of completing this activity, please
complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 12249.
Upon registering and successfully completing the post-test with a score
of 70% or better and the activity evaluation, your certificate will be
made available immediately. Processing credit requests online will
reduce the amount of paper used by nearly 100,000 sheets per year.
Disclosure of Unlabeled Use
educational activity may contain discussion of published and/or investigational
uses of agents that are not indicated by the FDA. The planners of this activity
do not recommend the use of any agent outside of the labeled indications.
opinions expressed in the educational activity are those of the faculty and do
not necessarily represent the views of the planners. Please refer to the
official prescribing information for each product for discussion of approved
indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
This activity is supported by an independent medical educational grant from Merck & Co.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.